340B Drug Pricing Program supports safety-net healthcare providers

The 340B Drug Pricing Program, established in 1992, requires pharmaceutical manufacturers to provide outpatient drugs at discounted prices to eligible safety-net healthcare organizations. These nonprofit entities serve high percentages of uninsured and low-income patients. The program is funded entirely by the pharmaceutical industry without taxpayer assistance.

Savings generated through the program allow healthcare systems to expand community services. Examples of funded initiatives include mental health clinics, diabetes education, mobile mammography, immunizations, and substance abuse counseling. Approximately 2,700 healthcare facilities participate in the program nationwide.

As the regulatory landscape evolves, covered entities face increasing scrutiny regarding documentation, manufacturer restrictions, and Medicaid billing exposure. Experts emphasize the need for updated policies and procedures to prevent audit findings, claim denials, and repayment risks caused by gaps between written guidance and actual operational workflows.